Trastuzumab — Drug Intelligence | 54 EU Trials

Filter these 54 trials by condition, phase, country and more.

Open in Search →

54 Registered trials

30 Recruiting

20 Completed trials

35 Sponsors

21 Countries

Phase III

Phase II

Phase III: 19 Phase II/III: 4 Phase II: 23 Phase I/II: 4 Phase IV: 3 Phase I (Other): 1

Oversight events:

2 serious breaches 5 temporary halts 2 unexpected events across 6 trials

View oversight register →

Indications tested

HER2 positive breast cancer 11 Breast cancer 4 Breast cancer stage III 3 Breast cancer stage II 3 Breast cancer metastatic 3 HER2 positive gastric cancer 2 Metastatic gastric cancer 2 Colorectal cancer metastatic 1 Gastrooesophageal cancer 1 Invasive breast carcinoma 1 Triple negative breast cancer 1 Cholangiocarcinoma 1

Sponsors using this IMP

Unicancer 5 AstraZeneca AB 4 F. Hoffmann-La Roche AG 4 Jazz Pharmaceuticals Ireland Limited 3 Karolinska University Hospital 3 Alx Oncology Inc. 2 Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting 2 Institut Curie 2 Institut Jules Bordet 2 Rigshospitalet 2 Seagen Inc. 2 Alliance Foundation Trials LLC 1

All trials

54 total

HER2 molecular imaging with 89Zr-trastuzumab PET/CT as a predictive biomarker for antibody-drug conjugate sequencing in patients with advanc… Not authorised

2024-516253-49-00 Phase II 1 country Institut Jules Bordet
A randomized, double-blinded, placebo-controlled, multicenter, phase II/III efficacy and safety study of oral TherO2-01S22 as add-on therapy… Pending

2024-516576-15-00 Phase II/III 1 country Centre Regional Lutte Contre Le Cancer
Tucatinib and trastuzumab in HER3-mutant and HER2-not amplified metastatic breast cancer Pending

2024-519624-24-00 Phase II 1 country Institut Curie
A Clinical Trial to Compare the Effectiveness and Safety of RO7771950 in Combination with Trastuzumab and Capecitabine, Versus Tucatinib in … Recruiting

2025-524498-17-00 Phase II/III 11 countries F. Hoffmann-La Roche AG
A Phase 2, randomized, multicenter, open-label neoadjuvant study evaluating zanidatamab in combination with chemotherapy in participants wit… Recruiting

2025-523204-68-00 Phase II 3 countries Jazz Pharmaceuticals Ireland Limited
HER2 molecular imaging with 89Zr-trastuzumab PET/CT as a predictive biomarker for antibody-drug conjugate sequencing in patients with advanc… Recruiting

2024-516253-49-01 Phase II 2 countries Institut Jules Bordet
HER2DX-guided diagnostic treatment For patients with HER2-positive early-stage breast cancer Recruiting

2025-521040-37-00 Phase III 4 countries Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques Augus…
The IPa-Gastric trial: Comparing Intraperitoneal Paclitaxel and Systemic Therapy versus Systemic Therapy alone in Gastric Cancer Patients wi… Recruiting

2024-514879-17-00 Phase III 4 countries Karolinska University Hospital
Beamion BCGC-1: A study to find a suitable dose of zongertinib used alone and in combination with other treatments to test whether it helps … Recruiting

2023-509566-38-00 Phase I/II 5 countries Boehringer Ingelheim International GmbH
Single arm phase 2 trial of neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positiv… Recruiting

2024-516582-36-00 Phase II/III 1 country Cancer Trials Ireland
A Study of Evorpacept (ALX148) in Patients with Metastatic HER2-Positive Breast Cancer Recruiting

2025-522012-16-00 Phase II 3 countries Alx Oncology Holdings Inc.
A trial comparing the treatment of rilvegostomig with fluoropyrimidine and trastuzumab deruxtecan to the standard treatment in patients with… Recruiting

2024-512583-57-00 Phase III 9 countries AstraZeneca AB
Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab versus Chemotherapy Plus Trastuzumab Plus or Minus … Recruiting

2024-513122-27-00 Phase III 12 countries Daiichi Sankyo Inc.
Decreasing treatment for metastatic HER2-Positive Breast Cancer with undetectable cancer levels in blood tests Recruiting

2023-509811-98-00 Phase II 1 country Unicancer
Safety of Trifluridine/tipiracil in patients with dihydropyrimidine dehydrogenase deficiency diagnosed with metastatic colorectal or gastroe… Recruiting

2023-508724-35-00 Phase II 1 country Unicancer
A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with phys… Recruiting

2023-508960-31-00 Phase III 8 countries Jazz Pharmaceuticals Ireland Limited
Evaluating the safety of shortened infusion tiMes for dIfferent oNcological immUnoThErapies; An observational prospective study Recruiting

2024-518878-14-01 Phase IV 1 country Isala Klinieken Stichting
A personalised approach based on blood and tumor characteristics to guide the post-surgical clinical path of patients with operable locoregi… Recruiting

2023-509851-15-00 Phase III 3 countries Ifom Istituto Fondazione Di Oncologia Molecolare Ets In Breve Ifom Ets
Personalized medicine for advanced biliary cancer patients Recruiting

2023-508100-38-00 Phase III 2 countries Unicancer
Treatment for breast cancer patients with meninges invaded by tumor cells Recruiting

2022-502351-60-00 Phase II 1 country Unicancer
Akynzeo as antiemetic treatment in patients with endometrial cancer treated with taxane - platinum combination chemotherapy. NOEME study. Recruiting

2023-504150-35-00 Phase IV 1 country Fondazione IRCCS Istituto Nazionale Dei Tumori
Tucatinib in combination with Oral Etoposide (VP16) and Trastuzumab in Patients with metastatic HER2+ Breast cancer (TUC-TOC) Recruiting

2022-500743-20-00 Phase II 1 country Institut Curie
Neoadjuvant trastuzumab, pertuzumab and tucatinib without chemotherapy in HER2-positive breast cancer: the TRAIN-4 study Recruiting

2024-518192-61-00 Phase I/II 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
A Randomized Trial of Trastuzumab Deruxtecan and Biology-Driven Selection of Neoadjuvant Treatment for HER2-positive Breast Cancer Recruiting

2022-501504-95-00 Phase II 3 countries Karolinska University Hospital

Showing 1–24 of 54 trials

← All drugs A–Z